



COURSE DIRECTORS
PROF. SIBEL ALPER, ISTANBUL, TURKEY
PROF. CLAU GARBE, TUEBINGEN, GERMANY

SECOND EUROPEAN SCHOOL OF DERMATO- ONCOLOGY, ORGANIZED BY EADO: FUNDAMENTALS OF CUTANEOUS ONCOLOGY

WWW.DERMATO-ONCOLOGY2014.ORG

FINAL PROGRAM

ISTANBUL, TURKEY
JANUARY 16TH-18TH, 2014
POINT HOTEL TAKSIM



Content

EADO European School of Dermato-Oncology	2
Target Audience	2
Educational Objectives	2
Course Organization	3
Program Overview	4
Program	6
Thursday, January 16 th , 2014	6
Friday, January 17 th , 2014	7
Saturday, January 18 th , 2014	9
EADO Dermato-Oncology Committee	11
Course Faculty	11
General Information	12
Sponsors	15
Registration Form	

EADO European School of Dermato-Oncology

The EADO is a non-profit organization funded in 1999 to promote, coordinate and improve clinical and laboratory research activities in the field of skin cancer including primary and secondary prevention, early detection, clinical diagnosis and clinical and experimental research. EADO has organized many successful meetings and the upcoming ones are visible on the website (www.eado.org). The EADO initiates for the second time a course dedicated to fundamentals in skin cancer targeted to specialists and residents in the final phase of their resident program. They will benefit a comprehensive and updated course to improve their decision-making process for the management of all types and stages of skin cancer, from diagnosis, primary treatment and adjuvant treatment, to the management of locoregional disease and distant metastatic disease. It is intended to organize this course every year in different countries.

Target Audience

This 2,5-day educational course targets doctors who are actively involved in the treatment of skin cancer. Dermatologists or other specialists who have completed specialist training, or residents in the final year of their training program, are likely to gain the most from this course.

The maximum number of delegates is 100. In order to make the course available throughout Europe, places will be made available on a first come first served basis to all applicants.

Educational Objectives

The principal aim of the course is to provide a comprehensive and detailed understanding of the decision-making process for the management of all types and stages of skin cancer. This will include diagnosis and primary treatment, management of locoregional disease and distant metastatic disease, and adjuvant treatment. This is particularly relevant given the rapid progress in our understanding of melanoma and non-melanoma skin cancer, and the development of new treatments. In particular delegates will acquire the following knowledge:

1. Strategies for diagnosis of melanoma, Merkel cell and non-melanoma skin cancer including dermoscopy and confocal laser microscopy.
2. The indications, risks and benefits and strategies for mole screening.
3. Diagnosis of skin cancer: how to break bad news.
4. The indications and methods for genetic diagnosis and genetic counseling of skin cancer patients.
5. The present AJCC staging systems and how to stage melanoma, Merkel cell and cutaneous squamous cell carcinoma, and other non-melanoma skin cancers.

6. The value of imaging and biomarkers for the detection of metastases and disease staging.
7. Adjuvant treatment of skin cancer: radiotherapy; immunotherapy; chemotherapy.
8. New systemic treatments for stage IV melanoma: targeted agents and immunotherapeutics.
9. New treatment options of advanced basal cell carcinoma.
10. New systemic treatments for advanced Merkel cell and squamous cell carcinoma.
11. The characteristics of mucosal and uveal melanomas and their treatment options.
12. Options for topical treatment of epithelial skin cancers.
13. The current classification of cutaneous lymphoma; staging and treatment options for different subtypes of cutaneous lymphoma.
14. Clinical trials in skin cancer: an update.
15. The indications and strategies for supportive treatments including best supportive care.

Course Organization

The course consists of plenary sessions and interactive outbreak sessions. Plenary sessions will comprise clear structured and up-to-date presentations followed by audience discussion. Voting devices will be used to respond to multiple choice questions. These questions may precede the presentation of the structured knowledge or may be presented at the end in order to test the level of knowledge the audience has gained.

The main part of the course consists of 8 interactive sessions, each with no more than 25 attendants. Every participant takes part in each of these sessions which mainly comprise case-based discussion. These will be used to illustrate treatment pathways, how risk and benefit are assessed, and how management decisions are made.



Sibel Alper, MD & Claus Garbe, MD
Course Directors

Program Overview

A commercial exhibition will be held on all days close to the meeting rooms.

	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00			
Thursday January 16th, 2014														
Group I							Welcome Session		COURSE A K. Peris		COURSE B C. Garbe			
Group II						LECTURE 1 J. Malvehy			COURSE B C. Garbe	Break	COURSE C A. Stratigos			
Group III						LECTURE 2 S. Şahin		Break	COURSE C A. Stratigos	Break	COURSE D R.Y. Anadolu			
Group IV									COURSE D R.Y. Anadolu		COURSE A K. Peris			
Friday January 17th, 2014														
Group I	LECTURE 3 V. del Marmol	LECTURE 4 I. Longo	LECTURE 5 C. Garbe	COURSE C A. Stratigos	COURSE D R.Y. Anadolu	Lunch	LECTURE 6 H. Pehamberger	LECTURE 7 E. Stockfleth	COURSE E J. Grob	COURSE F A. Hauschild				
Group II				Break	COURSE D R.Y. Anadolu				Break	COURSE A K. Peris	Break	COURSE F A. Hauschild	Break	COURSE G C. Lebbé
Group III				COURSE A K. Peris	COURSE B C. Garbe				COURSE G C. Lebbé	Break	COURSE H C. Robert			
Group IV				COURSE B C. Garbe	COURSE C A. Stratigos				COURSE H C. Robert	COURSE E J. Grob				
Saturday January 18th, 2014														
Group I	COURSE G C. Lebbé	LECTURE 8 C. Garbe	LECTURE 9 A. Hauschild	COURSE H C. Robert	LECTURE 10 J. Oldh	LECTURE 11 J. Becker	LECTURE 12 N. İfter	LECTURE 13 P. Arenberger	Lunch					
Group II	COURSE H C. Robert			Break								COURSE E J. Grob	Break	
Group III	COURSE E J. Grob			COURSE F A. Hauschild										
Group IV	COURSE F A. Hauschild			COURSE G C. Lebbé										

Lectures:	Giza Ballroom	Floor -1
Course A+E:	Babylon I	1st Floor
Course B+F:	Babylon II	1st Floor
Course C+G:	Giza Ballroom	Floor -1
Course D+H:	Fuji I	9th Floor

Program

Thursday, January 16th, 2014

13:45-14:00	PLENARY SESSION 1: Welcome and course introduction <i>Chairpersons: Claus Garbe and Sibel Alper</i>
14:00-14:30	LECTURE 1: Modern diagnostic tools for early detection of melanoma <i>Josep Malvehy, Barcelona, Spain</i>
14:30-15:00	LECTURE 2: Dermoscopic melanoma diagnosis <i>Sedef Şahin, Istanbul, Turkey</i>
15:00-15:30	Coffee Break
15:30-16:30	COURSE A: Oncogenetic diagnosis and mutational screening <i>Ketty Peris, L'Aquila, Italy</i>
15:30-16:30	COURSE B: Tumorbiopsy and sentinel node biopsy <i>Claus Garbe, Tuebingen, Germany</i>
15:30-16:30	COURSE C: Epithelial skin cancer: topical and medical treatments in early and advanced diseases <i>Alexander Stratigos, Athens, Greece</i>
15:30-16:30	COURSE D: Dermoscopy case presentations <i>Rana Yavuzer Anadolu, Ankara, Turkey</i>
16:30-17:00	Coffee Break
17:00-18:00	COURSE B: Tumorbiopsy and sentinel node biopsy <i>Claus Garbe, Tuebingen, Germany</i>
17:00-18:00	COURSE C: Epithelial skin cancer: topical and medical treatments in early and advanced diseases <i>Alexander Stratigos, Athens, Greece</i>
17:00-18:00	COURSE D: Dermoscopy case presentations <i>Rana Yavuzer Anadolu, Ankara, Turkey</i>
17:00-18:00	COURSE A: Oncogenetic diagnosis and mutational screening <i>Ketty Peris, L'Aquila, Italy</i>

Friday, January 17th, 2014

PLENARY SESSION 2

Chairpersons: Veronique del Marmol and Isabel Longo

08:00-08:30	LECTURE 3: Nevus screening and early detection of melanoma <i>Veronique del Marmol, Brussels, Belgium</i>
08:30-09:00	LECTURE 4: The current AJCC classification of skin tumors <i>Isabel Longo, Madrid, Spain</i>
09:00-09:30	LECTURE 5: Serologic and imaging diagnostics for tumor staging <i>Claus Garbe, Tuebingen, Germany</i>
09:30-10:00	Coffee Break
10:00-11:00	COURSE C: Epithelial skin cancer: topical and medical treatments in early and advanced diseases <i>Alexander Stratigos, Athens, Greece</i>
10:00-11:00	COURSE D: Dermoscopy case presentations <i>Rana Yavuzer Anadolu, Ankara, Turkey</i>
10:00-11:00	COURSE A: Oncogenetic diagnosis and mutational screening <i>Ketty Peris, L'Aquila, Italy</i>
10:00-11:00	COURSE B: Tumorbiopsy and sentinel node biopsy <i>Claus Garbe, Tuebingen, Germany</i>
11:00-11:30	Coffee Break
11:30-12:30	COURSE D: Dermoscopy case presentations <i>Rana Yavuzer Anadolu, Ankara, Turkey</i>
11:30-12:30	COURSE A: Oncogenetic diagnosis and mutational screening <i>Ketty Peris, L'Aquila, Italy</i>
11:30-12:30	COURSE B: Tumorbiopsy and sentinel node biopsy <i>Claus Garbe, Tuebingen, Germany</i>
11:30-12:30	COURSE C: Epithelial skin cancer: topical and medical treatments in early and advanced diseases <i>Alexander Stratigos, Athens, Greece</i>

12:30-14:00 Lunch

PLENARY SESSION 3

Chairpersons: Hubert Pehamberger and Eggert Stockfleth

14:00-14:30 **LECTURE 6: Treatment algorithms in metastatic melanoma**
Hubert Pehamberger, Vienna, Austria

14:30-15:00 **LECTURE 7: Surveillance and management of immunosuppressed patients**
Eggert Stockfleth, Berlin, Germany

15:00-15:30 Coffee Break

15:30-16:30 COURSE E: **Skin cancer prevention**
Jean-Jacques Grob, Marseille, France

15:30-16:30 COURSE F: **Adjuvant treatment with classical and pegylated IFN-alpha**
Axel Hauschild, Kiel, Germany

15:30-16:30 COURSE G: **Vemurafenib and other tyrosine kinase inhibitors**
Celeste Lebbé, Paris, France

15:30-16:30 COURSE H: **Ipilimumab/PD1 antibodies**
Caroline Robert, Paris, France

16:30-17:00 Coffee Break

17:00-18:00 COURSE F: **Adjuvant treatment with classical and pegylated IFN-alpha**
Axel Hauschild, Kiel, Germany

17:00-18:00 COURSE G: **Vemurafenib and other tyrosine kinase inhibitors**
Celeste Lebbé, Paris, France

17:00-18:00 COURSE H: **Ipilimumab/PD1 antibodies**
Caroline Robert, Paris, France

17:00-18:00 COURSE E: **Skin cancer prevention**
Jean-Jacques Grob, Marseille, France

Saturday, January 18th, 2014

08:00-09:00 COURSE G: **Vemurafenib and other tyrosine kinase inhibitors**
Celeste Lebbé, Paris, France

08:00-09:00 COURSE H: **Ipilimumab/PD1 antibodies**
Caroline Robert, Paris, France

08:00-09:00 COURSE E: **Skin cancer prevention**
Jean-Jacques Grob, Marseille, France

08:00-09:00 COURSE F: **Adjuvant treatment with classical and pegylated IFN-alpha**
Axel Hauschild, Kiel, Germany

PLENARY SESSION 4

Chairpersons: Claus Garbe and Axel Hauschild

09:00-09:30 LECTURE 8: **Oncogenetics and epidemiology of advanced basal cell carcinoma**
Claus Garbe, Tuebingen, Germany

09:30-10:00 LECTURE 9: **New treatment options for advanced basal cell carcinoma**
Axel Hauschild, Kiel, Germany

10:00-10:15 Coffee Break

10:15-11:15 COURSE H: **Ipilimumab/PD1 antibodies**
Caroline Robert, Paris, France

10:15-11:15 COURSE E: **Skin cancer prevention**
Jean-Jacques Grob, Marseille, France

10:15-11:15 COURSE F: **Adjuvant treatment with classical and pegylated IFN-alpha**
Axel Hauschild, Kiel, Germany

10:15-11:15 COURSE G: **Vemurafenib and other tyrosine kinase inhibitors**
Celeste Lebbé, Paris, France

11:15-11:30 Coffee Break

PLENARY SESSION 5

Chairpersons: Petr Arenberger and Jürgen Becker

11:30-12:00 LECTURE 10: **Rare cutaneous malignancies**
Judit Oláh, Szeged, Hungary

12:00-12:30 LECTURE 11: **Merkel cell carcinoma and dermatofibrosarcoma protuberans**
Jürgen Becker, Graz, Austria

12:30-13:00 LECTURE 12: **How to recognize cutaneous lymphomas**
Nilsel Ílter, Ankara, Turkey

13:00-13:30 LECTURE 13: **Cutaneous lymphoma treatment**
Petr Arenberger, Prague, Czech Republic

13:30-14:30 Lunch (with lunch box)

EADO Dermato-Oncology Committee

Sibel Alper, Istanbul, Turkey

Claus Garbe, Tuebingen, Germany

Judit Oláh, Szeged, Hungary

Hubert Pehamberger, Vienna, Austria

Course Faculty

Sibel Alper, Istanbul, Turkey

Petr Arenberger, Prague, Czech Republic

Jürgen Becker, Graz, Austria

Veronique del Marmol, Brussels, Belgium

Claus Garbe, Tuebingen, Germany

Jean-Jacques Grob, Marseille, France

Axel Hauschild, Kiel, Germany

Nilsel İter, Ankara, Turkey

Celeste Lebbé, Paris, France

Isabel Longo, Madrid, Spain

Josep Malvehy, Barcelona, Spain

Judit Oláh, Szeged, Hungary

Hubert Pehamberger, Vienna, Austria

Ketty Peris, L'Aquila, Italy

Caroline Robert, Paris, France

Sedef Şahin, Istanbul, Turkey

Eggert Stockfleth, Berlin, Germany

Alexander Stratigos, Athens, Greece

Rana Yavuzer Anadolu, Ankara, Turkey

General Information

Course Venue

Point Hotel Taksim
Topçu Caddesi No.2
34437 Taksim - Istanbul, Turkey
Phone: +90 212 313 5000
E-Mail: info@pointhotel.com
www.pointhotel.com/taksim/english/

Course Organization

MEDCONCEPT 

MedConcept Gesellschaft für medizinische Projekte mbH
Ms. Mirja Christ
Friedenstraße 58
15366 Neuenhagen b. Berlin, Germany
Phone: +49 (0)3342 42689-30
Fax: +49 (0)3342 42689-40
E-Mail: mirja.christ@medconcept.org; info@medconcept.org
www.medconcept.org

Hotel Accommodation

MedConcept has reserved a limited number of rooms at the Point Hotel Taksim.
Rate per standard room and night: 120 Euro single/130 Euro double, breakfast included.

Booking deadline: December 15, 2013

Reservation after this date will be subject to space and rate availability.

For your individual room booking, please follow the instructions given on the course website (www.dermato-oncology2014.org/Information/Accommodation).

Language and Translation

The official language of the meeting will be English. Simultaneous translation will not be provided.

Exhibition

A commercial exhibition will be held at the meeting venue, close to the main meeting rooms. If you are interested in participating as an exhibitor, please contact MedConcept's secretariat for further information.

Exhibition Opening Hours

Thursday, January 16: 13:00-18:30

Friday, January 17: 07:30-18:30

Saturday, January 18: 07:30-14:00

CME Credits

An application for CME accreditation will be made.

Cancellation Policy

Cancellations must be received in writing by December 17th, 2013. No refunds will be granted after that date. A processing fee of 30 Euro will be deducted from each cancelled registration. Substitutions are possible. To substitute a registration please send an email including the name of the original registrant and the name of the person substituting to mirja.christ@medconcept.org.


The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force, or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso.

Sponsors

Gold



Silver



Bronze




Further Sponsors

Almirall

Novartis

Amgen is researching ways
to help T cells target cancer.

Find it



T cell

Cancer cell

Reference: 1. Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. *Mol Ther* 2011;19:1008-1016.

Amgen (Europe) GmbH
Damnstrasse 23
CH-8300 Zug
Switzerland

©2013 Amgen Inc. All rights reserved. TVC-HQ-AMG-631-2013- November-1P

Fight it


ONCOLYTIC IMMUNOTHERAPY

is an innovative area of research that uses a modified virus designed to help T cells find and fight cancer cells as part of a hypothesized systemic, tumor-specific immune response.¹

AMGEN

Oncology

*Amgen. Leading the way
in the study of Oncolytic Immunotherapy.*



Almirall Dermatology

Staying ahead of ACTINIC KERATOSIS

 **Almirall**

Solutions with you in mind

www.almirall.com

Registration Form

Second European School of Dermato-Oncology, organized by EADO: Fundamentals of Cutaneous Oncology

Istanbul, Turkey, January 16th-18th, 2014

First Name: _____ Last Name: _____

Professional Title: _____ Degree: MD PhD RN PA-C

Gender: Male Female Speciality: _____

Institution: _____ Address: _____

City: _____ Zip Code: _____ Country: _____

Phone: _____ Fax: _____ E-Mail: _____

Fees

Registration Fee of **380,00 Euro** (incl. VAT) covers

- Admission to scientific sessions
- Admission to exhibition
- Bag with course documents
- Welcome reception
- Coffee breaks and lunch
- Certificate of Attendance

Payment Method

Bank Transfer: Registration can only be confirmed upon receipt of full payment.

Credit Card: MasterCard Visa American Express

Credit Card Number: _____

Expiration Date: _____

Security Code CCV: _____ (MC/Visa - 3 digits on back, AMEX - 4 digits on front)

Cardholder Name: _____

Signature: _____

An invoice will be sent by mail to the given address. If the invoice address is different from the address given above, please send an email including the name of the registrant and the full invoice address to mirja.christ@medconcept.org. By completing the registration form, the participant accepts the cancellation policy as stated in the course program.

To Register

Mail registration form to:

MedConcept GmbH, Friedenstraße 58
15366 Neuenhagen bei Berlin, Germany

Fax registration form to: +49 (0)3342 42689-40

Register online: www.dermato-oncology2014.org

